专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO0041114A9 ENVIRONMENTAL IMPACT AND BUSINESS ANALYSIS METHOD USING A STRATEGIC INFORMATION SYSTEM 审中-公开
标题翻译：使用战略信息系统的环境影响和业务分析方法
公开(公告)号：WO0041114A9
公开(公告)日：2002-08-22
申请号：PCT/US9931270
申请日：1999-12-30
申请人： GLASS DAVID SAUL
发明人： GLASS DAVID SAUL
IPC分类号： B09B5/00 , G06F17/30 , G06Q10/00 , G06F17/60
CPC分类号： G06Q10/06 , G06F2219/00
摘要： The invention (fig. 4-7) relates to a method of analysis of goods and services and business functions for the identification of cost (450, 540, 630, 724) and waste (435, 525, 625, 710), and more particularly to a method and apparatus for analysis of waste that impacts the environment and for identification of business opportunities (465, 555, 650, 745) to reduce or eliminate waste while increasing profitability. The method may be performed using a programmable computer.
摘要翻译：本发明（图4-7）涉及用于识别成本（450,540,630,724）和废物（435,525,625,710）的商品和服务和业务功能的分析方法，以及更多特别是一种用于分析影响环境和识别商业机会（465,555,650,745）的废物的方法和装置，以减少或消除浪费，同时提高盈利能力。该方法可以使用可编程计算机执行。

22. 发明申请

WO2016092439A1 MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA 审中-公开
标题翻译：用于治疗恐怖症的肌营养肽或活化拮抗剂
公开(公告)号：WO2016092439A1
公开(公告)日：2016-06-16
申请号：PCT/IB2015/059369
申请日：2015-12-04
申请人： NOVARTIS AG , KORTEBEIN, Patrick , ROOKS, Daniel , KLICKSTEIN, Lloyd B. , ROUBENOFF, Ronenn , GLASS, David , TRIFILIEFF, Estelle , PAPANICOLAOU, Dimitris
发明人： KORTEBEIN, Patrick , ROOKS, Daniel , KLICKSTEIN, Lloyd B. , ROUBENOFF, Ronenn , GLASS, David , TRIFILIEFF, Estelle , PAPANICOLAOU, Dimitris
IPC分类号： A61P21/00 , A61K39/395
CPC分类号： C07K16/2863 , A61K39/395 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/76 , C07K2317/90
摘要： The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.
摘要翻译：本发明涉及肌肉生长抑制素或激活素拮抗剂，剂量方案及其药物组合物，用于治疗肌肉减少症，特别是年龄相关的肌肉减少症。特别是，发现肌生长抑制素或激活素拮抗剂bimagrumab在增加骨骼肌力量和功能方面有利于治疗具有肌肉减少症的老年人。

23. 发明申请

WO2015157252A1 TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：使用抗CD19基因抗原受体治疗癌症
公开(公告)号：WO2015157252A1
公开(公告)日：2015-10-15
申请号：PCT/US2015/024671
申请日：2015-04-07
申请人： BROGDON, Jennifer , BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl, H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David, L. , RUELLA, Marco , SELLERS, William, Raj , WASIK, Mariusz
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl, H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David, L. , RUELLA, Marco , SELLERS, William, Raj , WASIK, Mariusz
IPC分类号： C12N5/0783 , A61K35/17 , A61K31/00 , A61P35/02
CPC分类号： A61K35/17 , A61K31/436 , A61K31/519 , A61K31/53 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N5/0636 , C12N2501/599 , C12N2501/727 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
摘要翻译：本发明提供了用于治疗与CD19表达相关的疾病的组合物和方法，例如通过如本文所述施用包含本文所述的CD19 CAR的重组T细胞与激酶抑制剂，例如本文所述的激酶抑制剂组合。本发明还提供了本文所述的试剂盒和组合物。

24. 发明申请

WO2015022658A3 METHODS OF TREATING SPORADIC INCLUSION BODY MYOSITIS 审中-公开
标题翻译：治疗体内包涵体神经系统的方法
公开(公告)号：WO2015022658A3
公开(公告)日：2015-05-28
申请号：PCT/IB2014063904
申请日：2014-08-13
申请人： NOVARTIS AG , PAPANICOLAOU DIMITRIS , ROUBENOFF RONENN , TSENG BRIAN , GUBSER CHARLES , GLASS DAVID
发明人： PAPANICOLAOU DIMITRIS , ROUBENOFF RONENN , TSENG BRIAN , GUBSER CHARLES , GLASS DAVID
IPC分类号： C07K16/28 , A61K39/395 , A61P21/00
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/545
摘要： The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
摘要翻译：本公开涉及用新方案治疗散发性包涵体肌炎和其它肌肉消瘦疾病，其使用治疗有效量的肌肉生长抑制素拮抗剂，例如肌肉生长抑制素结合分子，例如肌生成抑制素抗体或ActRII受体结合分子， ActRII受体抗体，例如bimagrumab抗体。

25. 发明申请

WO2015073644A1 MTOR INHIBITORS FOR ENHANCING THE IMMUNE RESPONSE 审中-公开
标题翻译： MTOR抑制剂用于增强免疫反应
公开(公告)号：WO2015073644A1
公开(公告)日：2015-05-21
申请号：PCT/US2014/065408
申请日：2014-11-13
申请人： NOVARTIS AG , MANNICK, Joan , GLASS, David, Jonathan , MURPHY, Leon
发明人： MANNICK, Joan , GLASS, David, Jonathan , MURPHY, Leon
IPC分类号： A61K45/06 , A61K31/436 , A61P35/00 , A61P37/04 , A61K39/00 , A61K39/09 , A61K39/145 , A61K31/4745 , A61K31/519 , A61K39/12
CPC分类号： A61K39/39 , A61K31/436 , A61K31/4745 , A61K31/519 , A61K39/00 , A61K39/09 , A61K39/092 , A61K39/12 , A61K39/145 , A61K45/06 , A61K2039/55511 , C12N7/00 , C12N2760/16034 , G01N33/6854
摘要： The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
摘要翻译：本发明部分地涉及通过部分mTOR抑制增强免疫应答的组合物和方法，例如用低剂量的免疫增强剂量的mTOR抑制剂如RAD001。

26. 发明申请

WO2013006437A1 METHOD FOR TREATING METABOLIC DISORDERS 审中-公开
标题翻译：治疗代谢障碍的方法
公开(公告)号：WO2013006437A1
公开(公告)日：2013-01-10
申请号：PCT/US2012/044929
申请日：2012-06-29
申请人： NOVARTIS AG , FEIGE, Jerome , GLASS, David , HATAKEYAMA, Shinji , RICHARDSON, Brian Peter , TRIFILIEFF, Estelle
发明人： FEIGE, Jerome , GLASS, David , HATAKEYAMA, Shinji , RICHARDSON, Brian Peter , TRIFILIEFF, Estelle
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/34 , C07K2317/76
摘要： The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters.
摘要翻译：本发明涉及包含抗ActRIIB抗体的组合物及其在脊椎动物中增加褐色脂肪的用途，包括啮齿动物和灵长类动物，特别是在人体中，而不显着影响血液学参数。

27. 发明申请

WO2011092234A1 METHODS AND COMPOSITIONS USING FGF23 FUSION POLYPEPTIDES 审中-公开
标题翻译：使用FGF23融合多肽的方法和组合物
公开(公告)号：WO2011092234A1
公开(公告)日：2011-08-04
申请号：PCT/EP2011/051112
申请日：2011-01-27
申请人： NOVARTIS AG , GLASS, David , HU, Shou-Ih
发明人： GLASS, David , HU, Shou-Ih
IPC分类号： C12N15/62 , G01N33/574 , G01N33/68
CPC分类号： C07K14/50 , A61K38/00 , C07K14/705 , C07K2319/00 , C07K2319/30 , C07K2319/32 , C12N9/2445 , C12N9/93 , C12Y302/00 , C12Y302/01021 , C12Y602/01003
摘要： The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q 156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage.
摘要翻译：本公开涉及用于预防或治疗年龄相关病症或代谢紊乱的方法，试剂盒和组合物。本公开的融合多肽包括FGF23或其活性片段。在一个实施方案中，融合多肽包含（a）包含成纤维细胞生长因子23（FGF23）或其功能活性变体或衍生物的多肽，其中FGF23在一个或多个位置Q 156，C206和C244处具有突变; 或（b）具有降低的对Fc-γ受体的亲和力和/或增加的血清半衰期的修饰的Fc片段或包含Klotho蛋白质的至少一个细胞外亚结构域的多肽或其功能活性变体或衍生物; 和（c）连接体。 Klotho融合蛋白可用于治疗和预防各种年龄相关病症和代谢紊乱。在另一个实施方案中，融合多肽包含FGF（如FGF23）或其功能活性变体或衍生物; 和修饰的Fc片段或其功能活性变体或衍生物。在融合多肽的各种实施方案中，FGF23具有减少聚集和蛋白酶介导的切割的突变。

28. 发明申请

WO2009095372A1 METHODS AND COMPOSITIONS USING KLOTHO-FGF FUSION POLYPEPTIDES 审中-公开
标题翻译：使用KLOTHO-FGF融合多肽的方法和组合物
公开(公告)号：WO2009095372A1
公开(公告)日：2009-08-06
申请号：PCT/EP2009/050850
申请日：2009-01-26
申请人： NOVARTIS AG , GLASS, David , HU, Shou-Ih
发明人： GLASS, David , HU, Shou-Ih
IPC分类号： C07K14/50 , C12N15/62 , A61K38/18
CPC分类号： C07K14/435 , A61K38/00 , C07K14/50 , C07K2319/00 , C12N9/2402 , C12Y302/01031
摘要： The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. The Klotho fusion proteins are useful in the treatment and preventionofa variety of age-related conditions and metabolic disorders.
摘要翻译：本发明涉及用于预防或治疗年龄相关病症或代谢紊乱的方法，试剂盒和组合物。本发明的Klotho融合多肽至少包括Klotho蛋白或其活性片段。 Klotho融合蛋白可用于治疗和预防多种年龄相关病症和代谢紊乱。

29. 发明申请

WO2007146689A3 STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES 审中-公开
标题翻译：稳定的胰岛素样生长因子多肽
公开(公告)号：WO2007146689A3
公开(公告)日：2008-04-10
申请号：PCT/US2007070468
申请日：2007-06-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , GLASS DAVID JONATHAN , FORNARO MARA
发明人： GLASS DAVID JONATHAN , FORNARO MARA
IPC分类号： A61K38/30 , C07K14/65
CPC分类号： C07K14/475 , A61K38/30 , C07K14/65
摘要： The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.
摘要翻译：本发明涉及具有IGF-1或IGF-2序列和E肽序列的稳定的多肽，其中预防了来自IGF的E-肽的天然生理切割。

30. 发明申请

WO2008021547A2 DUAL MODE SERVICE WIFI ACCESS CONTROL 审中-公开
标题翻译：双模服务无线访问控制
公开(公告)号：WO2008021547A2
公开(公告)日：2008-02-21
申请号：PCT/US2007/018384
申请日：2007-08-17
申请人： AT & T MOBILITY II LLC , GLASS, David , ABU-DAYYA, Adnan
发明人： GLASS, David , ABU-DAYYA, Adnan
IPC分类号： H04J1/05
CPC分类号： H04W4/04 , H04L67/306 , H04L67/32 , H04M7/006 , H04W4/90 , H04W8/18 , H04W8/26 , H04W8/265 , H04W12/08 , H04W60/005 , H04W64/00 , H04W76/50 , H04W84/12 , H04W88/06 , H04W88/08
摘要： Systems and methods are described that facilitate the provision of dual mode services. Access to the dual mode services is controlled by associating a mobile device to an access point. Subscribers are required to provide valid geographical addresses for access points associated with the mobile devices prior to provision of service. Consequently, physical addresses are necessarily available for emergency services (e.g., E911). Mobile devices are restricted to specific access points based upon the access point identifiers automatically provided during initialization of service and maintained for authorization purposes.
摘要翻译：描述了有助于提供双模式服务的系统和方法。通过将移动设备与接入点相关联来控制对双模业务的访问。在提供服务之前，用户需要为与移动设备相关联的接入点提供有效的地理地址。因此，物理地址必然可用于紧急服务（例如，E911）。移动设备基于在服务初始化期间自动提供的接入点标识被限制到特定接入点，并且为了授权目的而被维护。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式